AR and prostate cancer: Recently, in prostate cancer, MALAT1 was proposed to be a mediator of enzalutamide resistance through its indispensable role in AR-splice variant 7 (AR-V7) formation [47], and hence a potential target for pharmacological intervention in prostate cancer [48].